Literature DB >> 10994035

Flutamide-hydroxypropy-beta-chiyclodextrin complex: formulation, physical characterization, and absorption studies using the Caco-2 in vitro model.

Z Zuo1, G Kwon, B Stevenson, J Diakur, L I Wiebe.   

Abstract

PURPOSE: The objective of this research was to formulate flutamide (FLT) in hydroxypropyl-beta-cyclodextrin (HPbetaCyD), and to investigate FLT transcellular permeation from the complex using the Caco-2 monolayer in vitro model.
METHODS: Classical solubility data were used to derive thermodynamic parameters which, together with Differential Scanning Calorimetry (DSC), (1)H-NMR and (19)F-NMR, were used to characterize and derive stability constants for the FLT-HPbetaCyD complex. The Caco-2 cell line was used to examine the role of HPbetaCyD on the passage of FLT across cell monolayers in vitro.
RESULTS: The solubility of FLT in water (1.46 mmol/L) increased almost 170 times (to 243.45 mmol/L) in the presence of 50% (w/v) HPbetaCyD. Solubility data for FLT in aqueous HPbetaCyD were used to derive thermodynamic parameters (DeltaG degrees at 298 K = -3.48, DeltaH degrees = 2.85, DeltaS degrees at 298 K = 21.24). The solubility of FLT in HPbetaCyD increased proportionally with an increase in temperature. The FLT-HPbetaCyD complex had an A(L)-type (DSC) isotherm, consistent with a linear increase in FLT solubility and unchanged stoichiometry. The DSC of free FLT and HPbetaCyD showed endothermic peaks at 110 degrees C and 300 degrees C, respectively. FLT-HPbetaCyD did not display a free-FLT endothermic response, but exhibited broadening of the endothermic peak in the HPbetaCyD region. (19)F- and (1)H-NMR chemical shifts of FLT moved upfield as a function of its increased solubility in the presence of HPbetaCyD. The FLT-HPbetaCyD stability constant, K(s) (1:1) was estimated to be 356 M(-1 )and 357 M(-1), from thermodynamic and (19)F NMR data, respectively. The apical-to-basal permeability coefficient (P(eff) = 4.75 x 10(-5) cm.s(-1)) for FLT across Caco-2 cell monolayers at 37; C increased as HPbetaCyD concentrations were reduced, indicative of transepithelial passage via passive diffusion of available free FLT in solution. Studies in the presence and absence of Ca(2+ )ruled out a significant paracellular transport component.
CONCLUSIONS: FLT-HPbetaCyD is a relatively stable, 1:1 inclusion complex. Formation of this complex substantially increases the water solubility of FLT, but HPbetaCyD, except in high dilution, reduces transcellular passage of FLT in the Caco-2 cell in vitro model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994035

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  8 in total

1.  Preparation, characterization, and in vitro intestinal permeability evaluation of thalidomide-hydroxypropyl-β-cyclodextrin complexes.

Authors:  Jadel M Kratz; Marina R Teixeira; Karine Ferronato; Helder F Teixeira; Letícia S Koester; Cláudia M O Simões
Journal:  AAPS PharmSciTech       Date:  2011-12-09       Impact factor: 3.246

Review 2.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

3.  Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide.

Authors:  Tessa C A van Tongeren; Paul L Carmichael; Ivonne M C M Rietjens; Hequn Li
Journal:  Front Toxicol       Date:  2022-06-02

4.  Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.

Authors:  Samir G Patel; Sadhana J Rajput
Journal:  AAPS PharmSciTech       Date:  2009-05-21       Impact factor: 3.246

5.  Formulation and optimization of orodispersible tablets of flutamide.

Authors:  Kadria A Elkhodairy; Maha A Hassan; Samar A Afifi
Journal:  Saudi Pharm J       Date:  2013-02-10       Impact factor: 4.330

6.  Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics.

Authors:  Ahmed O Elzoghby; Maged W Helmy; Wael M Samy; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2013-05-03

7.  Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone.

Authors:  Devendra Kumar; Ashok K Khanna; Ram Pratap; Jitendra K Sexana; Rabi S Bhatta
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

8.  Per-6-Thiolated Cyclodextrins: A Novel Type of Permeation Enhancing Excipients for BCS Class IV Drugs.

Authors:  Mulazim Hussain Asim; Imran Nazir; Aamir Jalil; Flavia Laffleur; Barbara Matuszczak; Andreas Bernkop-Schnürch
Journal:  ACS Appl Mater Interfaces       Date:  2020-02-06       Impact factor: 9.229

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.